Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) shares fell 5.3% during mid-day trading on Thursday . The stock traded as low as GBX 180 ($2.39) and last traded at GBX 186.50 ($2.48). 13,146 shares were traded during trading, a decline of 63% from the average session volume of 35,549 shares. The stock had previously closed at GBX 197 ($2.62).
Faron Pharmaceuticals Oy Price Performance
The firm has a market cap of £250.92 million, a price-to-earnings ratio of -5.00 and a beta of 0.36. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The company's 50-day moving average price is GBX 212.66 and its 200-day moving average price is GBX 200.73.
Insider Activity
In related news, insider Markku Jalkanen sold 600,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of GBX 310 ($4.12), for a total value of £1,860,000 ($2,469,791.53). Corporate insiders own 31.82% of the company's stock.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Read More
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access